2、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 3、广州慧智微电子股份有限公司的主营业务是射频前端芯片及模组的研发、设计和销售。公司的主要 产品是5GUHB频段系列产品、5G重耕频段系列产品、4G频段系列产品、其他系列产品。 来源：新浪证券-红岸工作室 2月26日，慧智微涨3.39%，成交额1.85亿元，换手率4.40%，总市值61.16亿元。 异动分析 芯片概念+专精特新+5G+国家大基金持股+人民币贬值受益 1、公司主营业务为射频前端芯片及模组的研发、设计和销售。公司具备全套射频前端芯片设计能力和 集成化模组研发能力，技术体系以功率放大器（PA）的设计能力为核心。 主力没有控盘，筹码分布非常分散，主力成交额6100.89万，占总成交额的7.49%。 4、国家集成电路产业投资基金二期股份有限公司持2603万股，占总股本5.75%. 5、根据2024年年报，公司海外 ...

Core Viewpoint - The company, Guangzhou Huizhi Microelectronics Co., Ltd., specializes in the research, design, and sales of RF front-end chips and modules, with a significant focus on 5G technology and a strong market position as a "specialized, refined, distinctive, and innovative" enterprise [2][8]. Group 1: Company Overview - The main business of the company includes the development, design, and sales of RF front-end chips and modules, with key products in the 5G and 4G frequency bands [2][8]. - The company was established on November 11, 2011, and went public on May 16, 2023 [8]. - As of September 30, the company had 17,700 shareholders, an increase of 9.39% from the previous period [8]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 568 million yuan, representing a year-on-year growth of 48.04% [8]. - The net profit attributable to the parent company was -122 million yuan, showing a year-on-year increase of 58.98% [8]. - The company's overseas revenue accounted for 98.18%, benefiting from the depreciation of the RMB [4]. Group 3: Market Position and Recognition - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title in China for small and medium-sized enterprises [2]. - The National Integrated Circuit Industry Investment Fund holds 26.03 million shares, accounting for 5.75% of the total share capital [3]. Group 4: Technical Analysis - The average trading cost of the stock is 11.74 yuan, with recent chip reduction slowing down [7]. - The current stock price is near a resistance level of 12.21 yuan, indicating potential for a price correction if this level is not surpassed [7].

Core Insights - Ganyuan Food (002991.SZ) reported a revenue of approximately 945 million yuan for the first half of 2025, representing a year-on-year decline of 9.34% [2] - The net profit attributable to shareholders decreased by 55.20% to about 74.61 million yuan, indicating a significant drop in profitability [2] Company Overview - Ganyuan Food has focused on the research, production, and sales of snack foods since its establishment, leveraging its accumulated advantages in research, technology, scale, and management [2] - The company has expanded its product offerings from a single category of bean products to a diversified range that includes flavored nuts and puffed baked goods [2] Product Categories - The main product categories include: - Green pea series - Sunflower seed series - Broad bean series - Mixed nuts and bean series - Other products [2] - Core products such as green peas, sunflower seeds, and broad beans are popular among consumers due to their diverse flavors and specifications, catering to various regional and consumption scenarios [2] Financial Performance Factors - The decline in revenue and the increase in raw material costs, such as palm oil, have negatively impacted the gross profit margin during the reporting period [2]

Investment Rating - The report maintains a "Buy" rating for the company [4][5]. Core Views - The company is experiencing short-term pressure due to channel adjustments, but there is potential for recovery as the effects of these adjustments materialize [4]. - E-commerce growth remains strong, with a notable increase in direct sales and other channels, indicating resilience in key product lines despite overall revenue decline [1][2]. - The company is undergoing a transformation phase, focusing on direct sales and overseas market expansion, which is expected to yield positive results in the long term [4]. Revenue and Profitability - In the first half of 2025, the company achieved revenue of 940 million yuan, a year-on-year decrease of 9.3%, with a net profit attributable to shareholders of 75 million yuan, down 55.2% [1]. - The revenue from the e-commerce channel grew by 12.4% to 150 million yuan, showcasing strong performance amidst rising costs in the overall e-commerce landscape [1]. - The gross profit margin for the first half of 2025 was 33.6%, a decrease of 1.3 percentage points year-on-year, primarily due to cost pressures [3]. Cost and Expenses - The company faced increased cost pressures, particularly from rising palm oil prices, which averaged 9,462.2 yuan per ton, up 17.3% year-on-year [3]. - Selling expenses increased by 5.3 percentage points to 18.6% of revenue, driven by enhanced brand promotion efforts [3]. Future Outlook - The company is expected to see revenue growth of 3.0%, 20.4%, and 16.7% in 2025, 2026, and 2027, respectively, reaching 2.33 billion, 2.80 billion, and 3.27 billion yuan [4][9]. - Net profit is projected to decline by 12.9% in 2025 but recover with growth rates of 35.9% and 23.4% in the following years [4][9].

Group 1 - The company achieved revenue and net profit attributable to shareholders of 621 million and 247 million yuan in 2024, representing year-on-year growth of 30.0% and 41.9%, respectively, aligning with performance expectations [1] - In Q1 2025, the company reported revenue and net profit attributable to shareholders of 207 million and 95 million yuan, showing year-on-year declines of 26.5% and 34.8%, attributed to domestic policy adjustments and high base effects from Q1 2024 [1] - The gross profit margin for 2024 was 80.1%, an increase of 4.1 percentage points year-on-year, driven by a higher proportion of revenue from high-margin conventional products [1] Group 2 - The core respiratory product series generated revenue of 607 million yuan in 2024, reflecting a year-on-year increase of 30.8%, with continued market recognition and an expanding sales network [2] - Incremental businesses, including the prenatal and other series, achieved revenues of 4.17 million, 10.36 million, and 0.16 million yuan, with year-on-year growth rates of 0.8%, 7.4%, and a decline of 70.0%, respectively [2] - The company anticipates further growth in its incremental businesses in 2025, supported by new product approvals and enhanced sales promotion efforts [2] Group 3 - The company has successfully launched multiple new products in the chemical luminescence and PCR categories, enhancing its competitive position in the IVD market [3] - The company is increasing its investment in consumer-end business, establishing independent teams across product, R&D, and marketing to adapt to new home testing scenarios [3] - By the end of 2024, the company has established a significant presence in Southeast Asia and is advancing clinical trials and regulatory submissions for IVDR and FDA products in Europe and the U.S. [3] Group 4 - The company adjusted its EPS forecasts for 2025-2027 to 1.92, 2.21, and 2.53 yuan, reflecting a downward revision of 51% and 57% for 2025 and 2026, respectively, due to short-term revenue growth disruptions from domestic policy changes [4] - The company is assigned a target price of 40.23 yuan for 2025, based on a 21x PE ratio, compared to a previous target of 58.50 yuan [4]